Valuation: Samik Pharmaceutical Company LTD.

Market Cap 78.02B 58.04M 51.83M 48.35M 43.92M 82.65M 5.62B 83.45M 580M 227M 2.86B 218M 213M 9.19B P/E 2024 *
-
P/E 2025 -140x
Enterprise Value 48.97B 36.43M 32.53M 30.35M 27.57M 51.87M 3.53B 52.38M 364M 143M 1.79B 137M 134M 5.77B EV / Sales 2024 *
-
EV / Sales 2025 1.65x
Free-Float
40.35%
Yield 2024 *
-
Yield 2025 -
1 day-4.32%
1 week-11.33%
Current month-9.57%
1 month-11.43%
3 months+84.09%
6 months-21.08%
Current year-44.52%
1 week 7,720
Extreme 7720
9,080
1 month 7,540
Extreme 7540
12,050
Current year 3,705
Extreme 3705
21,800
1 year 3,705
Extreme 3705
25,050
3 years 3,705
Extreme 3705
25,050
5 years 3,705
Extreme 3705
25,050
10 years 3,705
Extreme 3705
25,050
Manager TitleAgeSince
Chief Executive Officer 64 30/11/2016
Chief Executive Officer 59 31/05/2011
Corporate Officer/Principal 56 31/07/2018
Director TitleAgeSince
Chairman 59 31/05/2011
Chairman 64 30/11/2016
Director/Board Member 66 29/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-4.32%-11.33% - - 58.04M
-1.61%+1.72%+38.30%+106.93% 1,043B
-0.76%-0.84%+35.21%+62.70% 618B
+0.39%+4.81%+17.81%+83.77% 481B
-0.29%-0.99%+64.79%+37.06% 351B
-2.03%+1.06%+21.08%+42.16% 338B
-1.92%-0.29%+10.54%+33.20% 269B
-2.36%-1.16%-7.14%+8.68% 244B
-1.37%+0.04%+38.29%+52.33% 220B
+0.17%-0.27%+24.40%+96.82% 182B
Average -1.39%-0.88%+27.03%+58.18% 374.67B
Weighted average by Cap. -1.04%+0.60%+30.46%+68.88%

Financials

2024 2025
Net sales 55.86B 41.55M 37.1M 34.61M 31.44M 59.17M 4.02B 59.74M 416M 163M 2.04B 156M 153M 6.58B 60.02B 44.65M 39.87M 37.19M 33.79M 63.58M 4.32B 64.2M 447M 175M 2.2B 168M 164M 7.07B
Net income 3.52B 2.62M 2.34M 2.18M 1.98M 3.73M 254M 3.77M 26.2M 10.25M 129M 9.84M 9.62M 415M -755M -562K -501K -468K -425K -800K -54.38M -807K -5.62M -2.2M -27.63M -2.11M -2.06M -88.87M
Net Debt -12.84B -9.55M -8.53M -7.96M -7.23M -13.6M -925M -13.74M -95.54M -37.37M -470M -35.87M -35.09M -1.51B -29.05B -21.61M -19.3M -18M -16.35M -30.77M -2.09B -31.07M -216M -84.54M -1.06B -81.14M -79.37M -3.42B
Projected Income Statement - Annual - Samik Pharmaceutical Company LTD.
Logo Samik Pharmaceutical Company LTD.
Samik Pharm Co Ltd is a Korea-based company engaged in the manufacturing and sales of pharmaceuticals business. The Company is mainly engaged in the manufacture of drugs such as circulatory machinery treatments such as Cesar Plus tablets and Eravix tablets, diabetes treatments such as Griffin tablets and Gluemser tablets, digestive machinery treatments such as Samik Pharmotidine tablets and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi tablets and Seklfen tablets. In addition, the Company is also engaged in the manufacturing of drugs such as treating acute or recurrent vaginal candidiasis, treating children with motion sickness, and treating alopecia. The Company sells its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
08/10/26 ₩7,750.00 -4.32% 290,926
07/10/26 ₩8,100.00 -3.57% 850,524
06/10/26 ₩8,400.00 -1.75% 338,658
02/10/26 ₩8,550.00 -2.17% 341,660
01/10/26 ₩8,740.00 +1.98% 526,008
  1. Stock Market
  2. Stocks
  3. A014950 Stock